Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 11/20 | 0.40 |
| ▸ | CPB1 | P15086 | 6/20 | 0.40 |
| ▸ | QPCT | Q16769 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14789411 | 0.89 | CPB2 (0.41) | CPB2CPB1QPCTMAOBWNT3A | |
| SCHEMBL14789403 | 0.87 | CPB2 (0.51) | CPB2CPB1PDE3BPDE3AALDH1A1 | |
| SCHEMBL14789459 | 0.86 | MAP4K4 (0.41) | CPB2CPB1QPCTKMT2ANOTUM | |
| SCHEMBL14789425 | 0.86 | CPB2 (0.41) | CPB2CPB1QPCTPDE3BPDE3A | |
| SCHEMBL14789483 | 0.86 | CPB2 (0.41) | CPB2CPB1 | |
| SCHEMBL14789624 | 0.86 | CPB2 (0.56) | CPB2CPB1MAOBALDH1A1 | |
| SCHEMBL14789635 | 0.85 | CPB2 (0.45) | CPB2CPB1MEN1KMT2AWNT3A | |
| SCHEMBL14789437 | 0.83 | CPB2 (0.44) | CPB2CPB1MAOBNOTUM | |
| SCHEMBL14790056 | 0.81 | CPB2 (0.40) | CPB2CPB1 | |
| SCHEMBL14789436 | 0.80 | CPB1 (0.37) | CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013039202-A1 | NOVEL ACRYLIC ACID DERIVATIVE | 第一三共株式会社 (JP) | 2013-03-21 | — | — | WO | disclosed |